At All Life Sciences, collaboration is at the core of everything we do. During our recent visit to India, while supporting a European GMP inspection, we also had the opportunity to meet with our long-standing partners at Orcimed Life Sciences (OMLS) and colleagues from Crescent Pharma.
Together, these organisations reflect the global scope of modern pharmaceutical services: Crescent as one of the UK’s leading generic medicine manufacturers with an established presence in UK, Malta and India; Orcimed as a provider of pharmacovigilance and clinical trial services with bases in both India and the United States; and All Life Sciences as the European and UK representatives for safety via provision of EU/UK QPPV, Deputy and Local safety officers services, bridging EU requirements with international operations.
Crescent Pharma: Scale and Strategic Presence
Crescent Pharma plays a critical role in the supply of affordable medicines. As one of the UK’s largest independent generic manufacturers, Crescent distributes over 200 million packs annually and holds 400+ UK marketing authorisations, covering around 120 active molecules with another 150 in development.
Their footprint extends beyond the UK. Through Crescent International in Malta, the company holds 30+ EU marketing authorisations, securing a robust European presence in the post-Brexit environment. Partnerships with India-based facilities further enhance their manufacturing and R&D capabilities, supporting both high-volume output and innovation.
This scale makes Crescent a strategic player in global healthcare — and underscores the importance of robust, inspection-ready pharmacovigilance systems.
Orcimed Life Sciences: Service Provider and Partner
Supporting Crescent in pharmacovigilance and clinical trials is Orcimed Life Sciences, a service provider established in both India and the United States. Orcimed ensures that global pharma companies meet international safety requirements while advancing research across diverse markets.
All Life Sciences complements this work by:
- Providing QPPV, Deputy QPPV, and Local Safety Officer contacts across Europe.
- Assisting in building inspection-ready systems, drawing on experience with multiple EU & UK authorities.
- Supporting regulatory transitions, such as the upcoming replacement of EU Regulation 520/2012.
The shared aim is clear: to protect patient safety and to secure the best inspection outcomes, ensuring continued and uninterrupted access to medicines worldwide.
Building Connections in Hyderabad
Partnerships are built not only on systems and compliance, but also on trust and human connection.
During our visit, key members of the Crescent, Orcimed, and All Life Sciences teams came together in central Hyderabad for an informal get-together over lamb biryani and other local dishes. These moments remind us that behind every inspection, report, or regulatory framework are people united by the same mission: safeguarding patients.
Lessons from the Salar Jung Museum
The visit also included time at Hyderabad’s renowned Salar Jung Museum, where among the artistic marvels available on display, one statue in particular stood out. From the front, it appeared to be a man; from behind, a woman. Two perspectives, one object.
For us, it became a powerful metaphor for pharmacovigilance — a discipline that depends on perspective and continuous re-evaluation.
- Perspective matters: clinical trials may suggest safety, while spontaneous reports reveal rare harms.
- Direct vs. indirect evidence: trial data shows what is expected; real-world sources uncover what is not.
- Two truths, one reality: a medicine can be both life-saving and risky, depending on context.
- Hidden details: subpopulation risks only emerge when we look closely.
- Constant re-inspection: safety profiles evolve with time, exposure, and new interactions.
Pharmacovigilance, like the statue, is about seeing both faces — the obvious and the hidden — and holding them together to form the full picture.
Looking Ahead
Our work with Orcimed and Crescent reflects the best of what collaboration in life sciences can achieve: a global manufacturer, a trusted service provider, and a regulatory partner working together to strengthen systems and protect patients.
At All Life Sciences, we remain committed to building these bridges across borders, ensuring that compliance and patient safety go hand in hand. Because whether in Malta, India, the UK, or the US, one truth remains constant: safe, trusted medicines depend on strong partnerships.
